Access to merge with MacroChem; Paratek plans expansion after move;

> Dallas-based Access Pharmaceuticals has forged a merger deal with MacroChem Corp. The deal is valued at $9 million. Both companies are engaged in developing new cancer therapies. Report

> The EMEA has approved CV Therapeutics' ranolazine for chronic angina. Report

> Protein Sciences has blasted back at Emergent BioSolutions, saying its lawsuit is nothing more than an attempt to "destroy and discredit PSC and its senior management team." Release

> Several biotech companies are on the move in Boston, including Paratek Pharmaceuticals, which is moving to a new location on the South Boston Waterfront and plans to hire some 50 workers over the next few years. Story

> Forbes.com offers a fresh take on the Enlight start-up, which is being backed by a trio of big pharma companies. "We have entered into this partnership because we believe it encourages the development of important enabling technologies and platforms which may otherwise not get developed due to the lack of early stage capital from traditional investors," said Pfizer in an email to Forbes.com. Report

> Dutch researchers say that the Schering-Plough hepatitis C drug Pegintron helped reduce the risk of a return of melanoma, the lethal skin cancer. Report

> Make way for Sanofi-Aventis. The French pharma has officially launched a $1.92 billion counterbid for Zentiva, the Czech generics maker. Report

> It was a close shave for 11 epilepsy drugs yesterday. An FDA advisory panel agreed that they may raise the risk of suicide -- but not enough to warrant a "black box" warning on their labels. Report

> Have a funny feeling that post-marketing safety studies are more and more prevalent these days? Well, it's not just a feeling. The Tufts Center for the Study of Drug Development found that drugmakers are increasingly bound to study their products after they hit the market. Report

> If you want a microcosmic view of pharma marketing to doctors, take a look at the numbers in Vermont. Over 12 months ended June 30, 2007, drugmakers spent $3.1 million to promote their meds through education and marketing mostly to physicians. Report

> Some time back we heard about the FDA handing out $35 million in bonuses under a new incentive-pay plan. Well, today CBS News has some details. Report

And Finally... A team of researchers has found a way to spot genes that help spread bird flu. Report

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.